Cost efficacy of tazobactam/piperacillin versus imipenem/cilastatin in the treatment of intra-abdominal infection

PharmacoEconomics

Volumn 19, Issue 1, 2001, Pages 79-94

  Dietrich, E S ^a   Schubert, B ^a   Ebner, W ^a   Daschner, F ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CILASTATIN PLUS IMIPENEM; PIPERACILLIN PLUS TAZOBACTAM;

ABDOMINAL INFECTION; ARTICLE; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DRUG COST; DRUG EFFICACY; HEALTH CARE COST; HUMAN; PRIORITY JOURNAL; RELAPSE;

EID: 0035150673     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200119010-00006     Document Type: Article

References (51)

1. Die behandlung der akuten eitrigen freien bauchfellentzuendung
2. A proposed classification of intra-abdominal infections
3. Intra-abdominal infections: An overview
4. Peritonitis and other intra-abdominal infections
5. Carbapenem: Monotherapy in intra-abdominal sepsis
6. Meropenem versus tobramycin versus clindamycin for treatment of intra-abdominal infections: Results of a prospective, randomized, doubleblind clinical trial
7. Imipenem/cilastatin. An update of its antibacterial activity, pharmacokinetics and therapeutic efficacy in the treatment of serious infections
8. Piperacillin/tazobactam: A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential
9. Parenterale antibiotika bei erwachsenen
10. Peritonitis: Update on pathophysiology, clinical manifestations, and management
11. Management of secondary peritonitis
12. Empfindlichkeitsspektrum von ceftriaxon und anderen antibiotika
13. Prospective randomized comparison of imipenem-cilastatin and piperacillin-tazobactam in nosocomial pneumonia or peritonitis
14. Piperacillin/tazobactam versus imipenem/cilastatin in the treatment of intra-abdominal infections
15. A randomized multicenter trial of piperacillin/tazobactam versus imipenem/cilastatin in the treatment of severe intra-abdominal infectious
16. Pharmakooekonomische untersuchung zum vergleich von piperacillin/tazobactam und imipenem/cilastatin bei der behandlung von patienten mit intraabdominellen infektionen
17. Clinical use of β-lactamase inhibitors in combination with extended-spectrum penicillins
18. Piperacillin/tazobactam: A critical review of the evolving clinical literature
19. Piperacillin/tazobactam: A new beta-lactam/beta-lactamase inhibitor combination
20. The safety profile of imipenem/cilastatin: Worldwide clinical experience based on 3470 patients
21. Safety profile of piperacillin/tazobactam in phase I and III clinical studies
22. Cost analysis of imipenem/cilastatin versus clindamycin with tobramycin in the treatment of acute intra-abdominal infection
23. Vergleichende untersuchung zum kosten-/effektivitaetsverhaeltnis einer initialen therapie mit imipenem/cilastatin bei der sekundaeren peritonitis
24. Imipenem/cilastatin versus gentamicin/clindamycin: A cost effectiveness study
25. Guidelines for clinical care: Anti-infective agents for intra-abdominal infections
26. Practical methodology of meta-analyses using updated individual patient data
27. Undertaking systematic reviews of research on effectiveness. CRD guidelines for those carrying out or commissioning reviews. CRD report no. 4
28. The practice of literature review
29. Literature review. A useful tool for the spine researcher
30. Randomized comparative trial of imipenem/cilastatin versus aminoglycoside plus amoxycillin plus clindamycin in the treatment of severe intra- and post-operative infections
31. Intravenous meropenem versus imipenem/cilastatin in the treatment of serious bacterial infections in hospitalized patients
32. Prospective, randomised, multicentre study of meropenem versus imipenem/cilastatin as empiric monotherapy in severe nosocomial infections
33. Prospective, randomized study of the comparative safety and efficacy of intraperitoneal imipenem versus vancomycin and netilmicin in the treatment of peritonitis on CAPD
34. Piperacillin-tazobactam versus imipenem-cilastatin for treatment of intra-abdominal infections
35. A randomized, doubleblind clinical trial comparing cefepime plus metronidazole with imipenem-cilastatin in the treatment of complicated intraabdominal infections
36. Imipenem/cilastatin (1.5 g daily) versus meropenem (3.0 g daily) in patient with intraabdominal infections: Results of a prospective, randomized, multicentre trial
37. Meropenem versus imipenem/cilastatin in the treatment of intra-abdominal infections
38. Biapenem versus imipenem/cilastatin in the treatment of complicated intra-abdominal infections: Report from a Swedish study group
39. Comparison of imipenem/cilastatin with the combination of aztreonam and clindamycin in the treatment of intra-abdominal infections
40. Meropenem versus imipenem/cilastatin in intra-abdominal infections requiring surgery
41. A comparison of imipenem/cilastatin with the combination of cefuroxime and metronidazole in the treatment of intra-abdominal infections
42. Meropenem versus imipenem/cilastatin in the treatment of intraabdominal infections requiting surgery
43. Results of a randomized trial comparing sequential intravenous/oral treatment with ciprofloxacin plus metronidazole to imipenem/cilastatin for intra-abdominal infections
44. Results of a prospective blinded rct comparing clinafloxacin (CLN) to imipenem/cilastatin (IMI) for complicated intra-abdominal infections
45. Piperacillin/tazobactam: New evidence for the management of intra-abdominal infection
46. Clinical efficacy and cost effectiveness of piperacillin/tazobactam vs. ampicillin + gemamicin + metronidazole in the treatment of intraabdominal infections
47. Monotherapy vs combination therapy in serious intraabdominal infections: A prospective randomized study
48. Management of intra-abdominal infections
49. Combining estimates of effect size
50. Antibiotikatherapie schwerer infektionen
51. Meta-analysis and quality of evidence in the economic evaluation of drug trials